On this page
When is a promotional reference-document submission appropriate?
Guidance IV.J describes follow-up for annotated materials missing from a previous submission, such as annotated references, promotional material or labeling. Identify the original tracking reference and exact pieces supported, and provide annotations matching the clean versions already submitted. If the entire promotional piece was omitted, use the missing-material correction assessment instead; references cannot substitute for the missing presentation.
Before you begin
Reference-document correspondence for missing annotated material described in IV.J. Entirely omitted promotional pieces require a different classification; this guide is not permission to replace a complete material submission with citations.
What you will prepare: A referenced follow-up with a precise attachment list and tested claim-to-source navigation.
Confirm the missing item is support
Compare the original submission with the requested correction. Identify whether the clean material was present but annotated material, labeling or references were missing. If the promotional piece itself was entirely omitted, use the missing-material amendment assessment instead. Record the original tracking reference and the agency communication that identified the gap, if any.
Write a short, specific follow-up
Identify the reference-document purpose, product/application, original submission/tracking reference and exactly which annotated artifacts are supplied. List the corresponding material IDs and versions. Explain any mismatch discovered during preparation; do not silently provide an annotated version of a newer claim as support for an older clean piece.
Test both directions of the evidence trail
Starting from a claim, open the cited source at the precise passage and inspect its context. Starting from a highlighted source, identify the claim it supports. Check study population, endpoint and limitations, and make sure the full source is available where appropriate. A highlight on a favorable sentence is not evidence that the whole promotional presentation is justified.
Fictional example: the wrong article version
A claim points to a conference abstract while the attachment is a later full paper with changed results. Record the discrepancy, obtain the intended source and reassess the claim with the content reviewer. Do not simply redirect the link and assume the newer paper supports the old wording.
Reconstruct the missing evidence trail without changing the claim
Before annotating anything, obtain the actual clean piece that reached FDA and the manifest for that submission. An internally approved later draft is not necessarily the version the reviewer has.
| Reconciliation step | Record | Failure to resolve |
|---|---|---|
| Original submission | Date, tracking reference and purpose | No reliable relationship to the earlier review |
| Clean material | ID, version and exact claim location | Support prepared for different wording |
| Missing support | Annotated piece, label or reference and expected role | Entirely missing material misclassified as a reference issue |
| Pinpoint locator | Source version, page, table or passage | Link opens a general document without locating support |
| Evidence context | Product, population, endpoint and relevant limitations | Favorable excerpt appears to support a broader claim than it does |
| Packaged navigation | Claim-to-source and source-to-claim relationship | Broken links or annotations after conversion |
Write the follow-up correspondence around those facts: original review identity, exact missing artifacts and associated material IDs, with any relevant agency request. Do not use the letter to bury an unreviewed substantive revision. If preparation reveals that the submitted claim lacks support, record the problem and obtain the appropriate content and routing decision.
Fictional evidence exercise: the clean piece reports an overall-population result, but the proposed annotation points to a favorable subgroup table. The file opens correctly and the study title matches. Those technical successes do not resolve the population mismatch. Locate support for the actual statement or route a reviewed content change through the appropriate process; do not relabel the subgroup result as the overall result to complete the reference package.
Preserve enough of the source to evaluate context. Check denominators, endpoint definitions, timepoints, analysis population and relevant uncertainty. Disease-background statements also need the right evidence where references are provided; a citation to the product label may not establish an epidemiologic claim. A highlighted sentence should not obscure a limitation in the neighboring paragraph.
After rendering, open each cited locator from the packaged annotated material, then confirm that a reviewer opening the reference can identify the claim it supports. Compare the text of clean and annotated pieces directly. If a missing support file is optional for the original final-reporting context, do not convert the existence of this follow-up route into a claim that all final 2253 reports universally require annotations.
Use the correction guide for entirely omitted pieces and the full evidence-package guide to coordinate all artifact roles.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Can a reference-document submission supply an entirely omitted promotional piece?
Guidance IV.J expressly distinguishes missing annotations from promotional materials entirely omitted from the previous submission. Assess an omitted piece through the missing-material correction workflow and the original purpose and format. Do not submit only references and assume they represent the advertisement the reviewer never received.
Should annotations match the latest internal draft or the clean piece FDA received?
For a missing-support follow-up, establish the actual submitted clean piece and prepare the corresponding evidence relationship. If the latest internal draft differs, disclose and resolve the revision through the appropriate process. An annotation to a newer claim is not support for an older differently worded presentation.
Does a working hyperlink prove that the claim is supported?
No. Open the source and assess the actual passage, population, endpoint, timepoint and limitations against the claim. A link can work perfectly while pointing to the wrong subgroup or an unsupported extrapolation. Technical navigation and scientific or regulatory adequacy require separate review.
Does this follow-up route make annotated references mandatory in every 2253 report?
No. The guidance distinguishes recommended draft-review support from optional annotations in final postmarketing reporting. Establish the original submission purpose and any actual agency request. The existence of a reference-document task does not turn every possible companion artifact into a universal final-reporting requirement.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA: Submissions of Promotional Labeling and Advertising ↗April 2022 final, Revision 1; IV.A–J, VI.E–H and VII. PDF production/PRA update April 2023 does not change the cover revision. Its legacy backbone syntax is not an eCTD v4 implementation guide. Checked September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.15.1.10. A heading identifies placement, not mandatory applicability.